Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing miceReport as inadecuate




Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice - Download this document for free, or read online. Document in PDF available to download.

BMC Cancer

, 9:85

First Online: 17 March 2009Received: 23 July 2008Accepted: 17 March 2009DOI: 10.1186-1471-2407-9-85

Cite this article as: Park, HR., Ju, EJ., Jo, SK. et al. BMC Cancer 2009 9: 85. doi:10.1186-1471-2407-9-85

Abstract

BackgroundAlthough cisplatin is one of the most effective chemotherapeutic agents, cisplatin alone does not achieve a satisfactory therapeutic outcome. Also cisplatin accumulation shows toxicity to normal tissues. In this study, we examined the possibility of HemoHIM both to enhance anticancer effect with cisplatin and to reduce the side effects of cisplatin in melanoma-bearing mice.

MethodsHemoHIM was prepared by adding the ethanol-insoluble fraction to the total water extract of a mixture of 3 edible herbs, Angelica Radix, Cnidium Rhizoma and Paeonia Radix. Anticancer effects of HemoHIM with cisplatin were evaluated in melanoma-bearing mice. We used a Cr-release assay to measure the activity of NK-Tc cell and ELISA to evaluate the production of cytokines.

ResultsIn melanoma-bearing mice, cisplatin 4 mg-kg B.W. reduced the size and weight of the solid tumors, and HemoHIM supplementation with cisplatin enhanced the decrease of both the tumor size p < 0.1 and weight p < 0.1. HemoHIM itself did not inhibit melanoma cell growth in vitro, and did not disturb the effects of cisplatin in vitro. However HemoHIM administration enhanced both NK cell and Tc cell activity in mice. Interestingly, HemoHIM increased the proportion of NK cells in the spleen. In melanoma-bearing mice treated with cisplatin, HemoHIM administration also increased the activity of NK cells and Tc cells and the IL-2 and IFN-γ secretion from splenocytes, which seemed to contribute to the enhanced efficacy of cisplatin by HemoHIM. Also, HemoHIM reduced nephrotoxicity as seen by tubular cell of kidney destruction.

ConclusionHemoHIM may be a beneficial supplement during cisplatin chemotherapy for enhancing the anti-tumor efficacy and reducing the toxicity of cisplatin.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-9-85 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Hae-Ran Park - Eun-Jin Ju - Sung-Kee Jo - Uhee Jung - Sung-Ho Kim - Sung-Tae Yee

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents